Alex Kesin and Matthew Pech
Approved
Life sciences, under the hood. Deep dives into the patent filings, regulatory gauntlets, and capital-risks that shape the business of biology.
Autor
Alex Kesin and Matthew Pech
Categoría
Web del podcast
Último episodio
14 de may. de 2026
¿Dónde escuchar?
Podcasts en la app Replaio Radio Muy prontoLos podcasts llegarán muy pronto a la app. Instálala ahora y sé el primero en descubrir una forma totalmente nueva de vivir los podcasts
Instálala gratis
Android 5 M+ de descargas · valoración de 4,8
iOS muy pronto
Episodios
Keytruda: How Merck's Pembrolizumab Became the Best-Selling Cancer Drug of All Time 14.05.2026 2:07:36
Keytruda is Merck's $31 billion a year PD-1 inhibitor and the best-selling cancer drug of all time. In Episode 3 of Approved , Alex Kesin and Matthew Pech trace the development of pembrolizumab , featuring interviews the scientists who drove the program forward : co-inventors Gregory Carven and Michel Streuli , and former Merck oncology CMO Roy Baynes . Topics include preclinical PD1 / CTLA-4 chec...
Episode #2: Geron 13.03.2026 2:22:06
Listen on Spotify Listen on Apple Podcasts Listen on YouTube TABLE OF CONTENTS (00:00:00) - Introduction (00:01:19) - Hayflick Limit (00:08:30) - Michael West & Founding of Geron (00:15:16) - Early Science & IP Strategy (00:27:25) - Cloning the Telomerase Gene (00:29:30) - Embryonic Stem Cells & Political Context (00:44:21) - Okarma, West’s Departure & Corporate Turmoil (01:...
Episode #1: Amylin Pharmaceuticals 30.01.2026 1:46:28
Listen on Spotify Listen on Apple Podcasts Listen on YouTube TABLE OF CONTENTS (00:00:00) - Introduction (00:04:40) - $50 of Dried Lizard Venom (00:29:17) - Fax of Death (00:43:04) - Sleeping Beauty Awakens (00:52:07) - Carl Icahn Sends a Letter (01:09:19) - Endgame (01:13:40) - Postmortem & Playbook CREDITS Co-hosted by Alex Kesin and Matthew Pech Written, edited, and produced by Alex Kesin...
Podcasts similares
Escucha el podcast Approved en Replaio
Radio y podcasts en una sola app - gratis y sin registro. Instálala hoy y no te pierdas el estreno
Replaio no es editor de podcasts; los nombres de los programas, las portadas y el audio pertenecen a sus autores y se distribuyen a través de canales RSS públicos
